The biotech industry is comprised of government funded research centers, dominant domestic and international players, and small private companies established mainly by researchers who have returned from abroad. Typically, angel investors or venture capitalists that initially finance these smaller companies do not have a proper exit strategy to enter the capital markets resulting in a financial crunch in the later stages. Additionally, some of these firms are not financially prepared to raise funds through foreign capital markets where they have to adhere to international regulations such as the Sarbanes Oxley act, which in itself is an expensive process.

However, these companies can consider a mix of financing options overseas such as the Alternative Investment Market (AIM) in London, which offers capital for emerging-market companies. Increasingly, Asian companies that felt frustrated by the lack of funding in their own markets are turning to international sources of financing and advice. With the right mix of financing vehicles, they will have a better chance of seeing their innovations reach a wider customer base worldwide. Many Asian governments are aware of funding issues faced by small and medium-sized biotech enterprises and have plans to implement policies to support and guide these companies on commercialisation hurdles, finance and grants.

With the biomedical industry booming in the region and extensive financial and other support from Asian governments, international investors are again eyeing the biotech industry in this region. Thus it is timely to launch BioInvest Asia 2008 which focuses on biotech investment in Asia, uncovering the full potential of investment opportunities available & find out where biotechs can gain insights on how to raise funds through various channels and models.

BioInvest Asia 2008 will bring together private equities, venture capitalists, biotech funds and other professional investors with leading public and private biotech companies who are looking to raise capital from Asia and globally, to explore investment opportunities offered by  Asia’s burgeoning biomedical industry. This will be the ONLY event in Asia where capital meets new business opportunities in the area of  innovative therapeutics, diagnostics and medical technologies from Asia Pacific and globally.

BioInvest Asia 2008 provides ONE platform where supporting regional agencies and biotechs from Singapore, Australia, New Zealand, India, China, Japan, Taiwan, Hong Kong, Korea, Malaysia and Thailand will look for partnership opportunities 

Speaking opportunities are now available. For more information, please contact Tingting Wang on +65 6322 2775 or email tingting.wang@terrapinn.com